Nutritional composition capable of improving DHA enrichment degree of eye and brain tissues and application of nutritional composition

Abstract

The invention relates to a nutritional composition capable of improving DHA enrichment degree of eye and brain tissues and application of the nutritional composition. The nutritional composition contains linoleic acid, a-linolenic acid, selenium element and DHA (docosahexaenoic acid), the content of the linoleic acid is 160 to 1000 parts by mass, the content of the alpha-linolenic acid is 18 to 110 parts by mass, and the content of the DHA is 20 to 350 parts by mass; the mass ratio of the DHA to the selenium element is (3000 to 40000) to (1 to 16). According to the nutritional composition, through the synergistic effect of the linoleic acid, the linolenic acid and the DHA in a specific proportion, the organism conversion efficiency of the DHA can be improved, efficient enrichment of the DHA in eye brain tissues is achieved, and the BDNF level of the eye brain tissues is remarkably improved.

Description

Technical Field

[0001] The present invention relates to a nutritional composition capable of improving the DHA enrichment of eye and brain tissues and application thereof, belonging to the technical field of nutritional foods. Background Art

[0002] Docosahexaenoic acid (DHA) belongs to n-3 long-chain polyunsaturated fatty acids (LCPUFAs). It is an important fatty acid component in the brain, nerves and visual cells. It plays an important role in the normal functioning of human physiological functions and the prevention and treatment of various diseases. It plays an important role in the development of the brain and retina in early life.

[0003] Fatty acids that are indispensable to the human body and cannot be synthesized by the body and must be supplied by food are called essential fatty acids (EFA). Essential fatty acids include n-6 series fatty acids linoleic acid and n-3 series fatty acids α-linolenic acid. Other polyunsaturated fatty acids with important physiological functions, such as DHA and n-6 ​​long-chain polyunsaturated fatty acids eicosatetraenoic acid (Arachidonic acid, ARA), can be converted from essential fatty acids. However, since the synthesis of DHA and ARA in the body uses the same series of enzymes, and mammals lack Δ 12 or Δ 15 Desaturase, n-3 series and n-6 ​​series fatty acids cannot be converted into each other, so there is competitive inhibition in the synthesis of DHA and ARA in the body, and the efficiency of linolenic acid conversion to DHA is low, so obtaining DHA directly from food is the most effective way. At present, there is an urgent need to study a nutritional formula that can achieve efficient enrichment of DHA in the body's eye and brain tissues. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a nutritional composition, which can achieve efficient enrichment of DHA in eye and brain tissues and significantly improve the BDNF level of eye and brain tissues through the synergistic effect of linoleic acid, linolenic acid, selenium and DHA in specific proportions.

[0005] To achieve the above object, the present invention provides a nutritional composition capable of increasing the DHA enrichment in eye and brain tissues, wherein the nutritional composition contains linoleic acid, a-linolenic acid, selenium and DHA;

[0006] In parts by mass, the linoleic acid is 160-1000 parts, the a-linolenic acid is 18-110 parts, and the DHA is 20-350 parts;

[0007] The mass ratio of DHA to selenium is (3000-40000):(1-16).

[0008] In the above nutritional composition, preferably, the mass ratio of linoleic acid to a-linolenic acid is 5:1-11:1, more preferably 6:1-9:1.

[0009] In the above nutritional composition, preferably, based on parts by mass, the linoleic acid is 300-900 parts, the a-linolenic acid is 40-100 parts, and the DHA is 30-250 parts.

[0010] In the above nutritional composition, preferably, the mass ratio of DHA to selenium is (10000-40000):(5-15).

[0011] In the above nutritional composition, preferably, the source of DHA is selected from one or a combination of two or more of milk-derived DHA, algae, tuna oil, fish oil, egg yolk extract, and krill oil, which are biologically transformed by feed nutrition regulation. Among them, the algae can include one or a combination of two or more of Schizochytrium, Oukenhofensis, and Crypthecodinium cohnii.

[0012] In the above nutritional composition, preferably, the milk-derived DHA biotransformed by feed nutrition regulation is native DHA raw milk.

[0013] In the above nutritional composition, preferably, the native DHA raw milk is prepared according to the feeding and management method of dairy cows in CN 105660520 B, such as Example 2 in CN 105660520 B.

[0014] In the above nutritional composition, preferably, the source of the linoleic acid includes one or a combination of two or more of soybean oil, walnut oil, corn oil, wheat germ oil, sunflower oil, cottonseed oil, sesame oil, peanut oil, rice bran oil and rapeseed oil.

[0015] In the above nutritional composition, preferably, the source of the a-linolenic acid includes one or a combination of two or more of soybean oil, walnut oil, rapeseed oil, linseed oil, perilla oil, peony seed oil and sacha inchi oil.

[0016] In the above nutritional composition, preferably, the nutritional composition contains phospholipid DHA; based on the total DHA content of the nutritional composition, the content of the phospholipid DHA is 10wt% or more, more preferably 15wt% or more, and further preferably 15wt%-30wt%.

[0017] In the above nutritional composition, preferably, the source of the selenium element includes one or a combination of two or more of sodium selenite, sodium selenate, selenoprotein, selenium-enriched edible fungus powder, L-seleno-methylselenocysteine, selenized carrageenan, and selenium-enriched yeast.

[0018] The present invention also provides the use of the above-mentioned nutritional composition in the preparation of foods capable of increasing the enrichment of DHA in eye and brain tissues. Preferably, the increased enrichment of DHA in brain tissues refers to the use of the nutritional composition in foods that enhance the enrichment of DHA in eye and brain tissues in early life.

[0019] The present invention also provides the use of the nutritional composition in preparing food capable of improving the BDNF level of eye and brain tissues.

[0020] According to a specific embodiment of the present invention, preferably, the food includes one or a combination of two or more of infant complementary food, dietary supplements, infant formula powder, infant yogurt, infant cheese, premature infant nutritional fortifier, premature infant formula powder, infant special medical food, health food, dairy products, milk beverages, snack foods, and pet food.

[0021] According to a specific embodiment of the present invention, preferably, in the food, the content of DHA is ≥10 mg / 100 g, and the dosage of selenium is 5-28 μg / 100 g; more preferably, the content of DHA is 10-40 mg / 100 g, and the dosage of selenium is 5-15 μg / 100 g.

[0022] Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family and plays an important role in the growth, differentiation, survival and repair of neurons after injury. BDNF can regulate proteins related to neurogenesis, learning and memory, and neuronal survival, and plays an important role in synaptic structure and function and neurogenesis. Its expression level is positively correlated with cognitive function.

[0023] The present invention provides a composition for improving the DHA enrichment of eye and brain tissues in early life and improving the BDNF level of eye and brain tissues. The composition is composed of linoleic acid, linolenic acid, selenium and DHA in a certain content and ratio. The sources of DHA include fish oil DHA, algae oil DHA and milk-derived DHA biotransformed by feed nutrition regulation.

[0024] The nutritional composition of the present invention can improve the body's conversion efficiency of DHA through the synergistic effect of linoleic acid, linolenic acid, selenium and DHA in a specific ratio, achieve efficient enrichment of DHA in eye and brain tissues, and significantly increase the BDNF level of eye and brain tissues. DETAILED DESCRIPTION

[0025] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical solution of the present invention is now described in detail below, but it should not be construed as limiting the applicable scope of the present invention.

[0026] The present invention provides examples and comparative examples, and compares and analyzes the enrichment of DHA in brain tissue and the expression level of BDNF in eye and brain tissue under different linoleic acid, linolenic acid, selenium and DHA intervention doses and DHA compositions.

[0027] Experimental content:

[0028] 1) Experimental animals

[0029] Bama miniature pigs, one month old (just weaned), 5 in each group, male, with consistent initial body weight, and body weight variation range not exceeding 10% of the average body weight.

[0030] 2) Animal rearing conditions and grouping

[0031] The pig feed used in this study is a customized feed, and DHA is strictly controlled in the feed. The feed formula and main index data are shown in Table 1. The polyunsaturated fatty acids supplemented by the samples of the embodiments and comparative examples, and the total polyunsaturated fatty acids in the diet (i.e., experimental grouping and intervention dose) are shown in Table 2 and Table 3 respectively. The fats in the feed used in Comparative Example 1, Comparative Example 3, Comparative Example 4 and Example 1 are composed of 50% soybean oil, 25% rapeseed oil, 9% peanut oil, 9% palm oil, 5% corn oil, and 2% cottonseed oil. The above formula is formulated based on the Chinese residents' vegetable oil consumption structure data in the reference literature and statistical reports. The fats in the feed of Comparative Example 2 are composed of soybean oil. Bama miniature pigs were raised according to the standard scheme. During the feeding process, the daily feed intake of each pig was controlled to be the same, and water was freely available. The experiment began after 8 days of adaptive feeding. The test substance (cow's milk) was artificially given, and the daily feeding dose of the test substance was adjusted according to the weight of the animal. Dosing cycle: 90 days.

[0032] Table 1 Pig feed formula

[0033] Element content corn 76％ Soybean meal 20％ Premix (Debao Qunxing, 1402H) 4％ total 100％ Crude protein (%) 15.79 Digestible energy (DE, Mcal / kg) 3.27 DHA -

[0034] Table 2 Polyunsaturated fatty acids and selenium supplemented in each sample

[0035]

[0036] The lower limit in Table 2 above is the mass of nutrients supplemented at 3 kg body weight at the initial feeding stage, and the upper limit is the mass of nutrients supplemented at 16 kg body weight at the end of feeding. Based on the comparison of the technical effects of the comparative examples and the embodiments, the mass range of linoleic acid and linolenic acid is between Example 1 and Comparative Example 2, and the mass range of DHA is within the range of Example 1. Based on the total dietary data in Table 3, the preferred ratio of linoleic acid / a-linolenic acid is between 6:1 and 9:1.

[0037] Table 3 Total polyunsaturated fatty acids and selenium in each sample diet

[0038]

[0039] In Table 3, the milk of Comparative Example 1 is ordinary pure milk, the content of linoleic acid and linolenic acid in the feed of Comparative Example 2 is more sufficient than that of other comparative examples and embodiments, the milk used for feeding is ordinary pure milk, the milk fortified with DHA added in Comparative Example 3 is ordinary pure milk with additional fish oil DHA component, the milk fortified with DHA added in Comparative Example 4 is ordinary pure milk with additional algae oil DHA component, and the milk fortified with DHA added in Example 1 is native DHA raw milk.

[0040] 3) Weight monitoring

[0041] The animals were weighed before the experiment and then weighed every 3 days on an empty stomach to calculate the average body weight and weight gain at each stage, and the amount of milk, feed and oil fed was adjusted at any time according to the changes in the animal's weight.

[0042] 4) Determination of DHA enrichment in eye and brain tissues

[0043] All animals were killed and dissected on the last day of the experiment. Immediately after the dissection, blood samples were taken and placed in anticoagulant blood collection tubes, and immediately processed into plasma samples for freezing and storage. After blood collection, the heart was perfused with normal saline. After the perfusion was completed, eye tissue (the retina needed to be further separated) and brain tissue samples were taken, weighed and recorded, and quickly frozen in liquid nitrogen and stored at -80°C for later use.

[0044] 5) Total DHA content test in tissues

[0045] Weigh about 200 mg of each tissue sample into a 2 mL BBI homogenizer tube, and add deionized water at a material ratio (m / m) of 1:2. Place the homogenizer tube in a homogenizer at 8000 rpm, run for 15 seconds and pause for 5 seconds, for a total of 100 seconds. Pipette 100 μL of the tissue homogenate in the BBI homogenizer tube into a 1.5 mL sterile enzyme-free centrifuge tube for later use.

[0046] In a centrifuge tube containing 100 μL of tissue homogenate, add 250 μL of chloroform and 500 μL of methanol, mix well, and sonicate with an ultrasonic instrument for 5 minutes. Add 250 μL of chloroform and sonicate for 5 minutes. Add 250 μL of deionized water and sonicate for 5 minutes. Centrifuge the sample at 13000 rpm for 5 minutes, and draw 400 μL of the lower chloroform layer into a 2 mL centrifuge tube and blow dry with a nitrogen blower. Add 0.1 mL of toluene to the nitrogen-dried sample to re-dissolve, add 0.5 mL of 10% acetyl chloride-methanol solution, place in a metal incubator, incubate at 60°C for 1 hour. After the incubation, transfer the sample to a 5 mL centrifuge tube, add 0.8 mL of n-hexane and 0.8 mL of deionized water in turn, vortex and extract for 5 minutes, and centrifuge at 5000 rpm for 5 minutes after the vortexing. After the centrifugation, draw 150 μL of the upper n-hexane layer into the sample for testing.

[0047] Take the DHA methyl ester standard series working solution and sample solution and inject them into the gas chromatograph respectively. The chromatographic conditions are as follows. Capillary column: polydicyanopropylsiloxane strong polar stationary phase, column length 100m, inner diameter 0.25mm, film thickness 0.2μm. Injector temperature: 270℃, detector temperature: 260℃. Program temperature rise: initial temperature 130℃, last 5min; 130℃-240℃, heating rate 4℃ / min, hold 20min. Carrier gas: nitrogen, split ratio: 100:1. Injection volume: 1.0μL.

[0048] A linear regression standard curve was drawn with the chromatographic peak area of ​​the DHA methyl ester standard as the ordinate and the concentration as the abscissa. The chromatographic peak area of ​​the target substance in the sample was substituted into the linear equation of the standard curve to calculate the concentration of the sample to be tested, and the actual content of the target substance in the sample was calculated according to the sampling amount. The calculation formula is shown in Formula 1.

[0049]

[0050] Where:

[0051] X8—total DHA content in tissue, mg / g;

[0052] c—sample concentration, μg / mL;

[0053] V0—volume of n-hexane in the extract, 0.8 mL;

[0054] V1—chloroform volume before extraction, 0.5 mL;

[0055] V2—the volume of chloroform before nitrogen blowing, 0.4 mL;

[0056] m—tissue weight, mg.

[0057] 6) Determination of brain-derived neurotrophic factor (BDNF)

[0058] The BDNF level in the eye and brain tissue of Bama miniature pigs was determined using the porcine brain-derived neurotrophic factor ELISA kit (CUSABIO, CSB-EL002655PI). The determination process is briefly described as follows: 100 mg of brain tissue / eye tissue was taken, rinsed with PBS, homogenized in 0.5 mL PBS, and stored at -20°C overnight. After two freeze-thaw cycles to destroy the cell membrane, the homogenate was centrifuged at 5000g and 4°C for 5 min, and the supernatant was removed and immediately analyzed. 100 μL of standard (gradient concentration) or sample supernatant was added to each well of the provided 96-well plate, covered with a sealing film, and incubated at 37°C for 2 h. The liquid in each well was removed without washing the plate. 100 μL of biotin antibody was added to each well and covered with a new sealing film. Incubate at 37°C for 1 h. The liquid in each well was removed and the plate was washed 3 times with washing buffer. Add 100 μL HRP-avidin to each well, cover with a new plate sealer, and incubate at 37°C for 1 hour. Remove the liquid in each well and wash the plate 5 times with wash buffer. Add 90 μL TMB substrate to each well, cover with a new plate sealer, and incubate at 37°C in the dark for 15-30 minutes. Add 50 μL of reaction stop solution to each well, tap the plate gently to ensure full mixing, and measure the absorbance of each well within 5 minutes at 450 nm. Draw a standard curve with absorbance as the horizontal axis and standard BDNF concentration as the vertical axis, and then calculate the BDNF concentration of the sample homogenate according to the absorbance value of the sample well, and then calculate the BDNF level in the tissue sample. The calculation formula is shown in Equation 2.

[0059]

[0060] Where:

[0061] X9—BDNF content in tissue, μg / g;

[0062] c—BDNF concentration of sample homogenate, ng / mL;

[0063] V—sample homogenate volume, 0.5 mL;

[0064] m—homogenized tissue weight, 0.1 g.

[0065] 7) Statistics

[0066] Software was used for statistical analysis of data and plotting of experimental results. The mean and standard deviation of each group of data were calculated using the software. ANOVA analysis and LSD test (homogeneity of variance) / Dunnett's T3 test (non-homogeneity of variance) were used to statistically analyze the significance of the differences between the data groups. The experimental results were expressed as mean ± standard deviation (Mean ± SD), and p ≤ 0.05 and p ≤ 0.01 indicated significant and extremely significant statistical differences, respectively. Correlation analysis was performed between the data, and Pearson was selected for the correlation coefficient, and two-tailed was selected for the significance test condition.

[0067] 8) Experimental results

[0068] The DHA enrichment in eye and brain tissues and the BDNF levels in eye and brain tissues of different groups are shown in Tables 4 and 5, respectively.

[0069] Table 4 DHA enrichment in eye and brain tissues of different groups

[0070]

[0071]

[0072] Note: Data are expressed as mean ± standard deviation (Mean ± SD) (n = 4). Different superscript letters in each column indicate statistical differences between the data groups (uppercase letters indicate p ≤ 0.01, lowercase letters indicate p ≤ 0.05) Table 5 BDNF levels in eye and brain tissues of different groups

[0073]

[0074] Note: Data are expressed as mean ± standard deviation (Mean ± SD) (n = 4). Different superscript letters in each column indicate statistical differences between groups of data (capital letters indicate p ≤ 0.01, lowercase letters indicate p ≤ 0.05)

[0075] From the data in Table 4 and Table 5, we can see that:

[0076] Comparative Example 1 is a model of essential fatty acid linoleic acid and linolenic acid deficiency established by simulating the daily oil intake of Chinese residents. The DHA content in the brain tissue of this comparative example is significantly lower than that in Comparative Example 2, Comparative Example 3 and Example 1, and the DHA content in the retina is significantly lower than that in Comparative Example 3 and Example 1; the BDNF level in the brain tissue is significantly lower than that in Comparative Example 2, Comparative Example 3, Comparative Example 4 and Example 1, and the BDNF level in the eye tissue is significantly lower than that in Comparative Example 3 and Example 1.

[0077] Comparative Example 2 is a case of supplementing a certain amount of linoleic acid and linolenic acid. In this comparative example, the DHA content of brain tissue is significantly higher than that of Comparative Example 1, and there is no significant difference with Comparative Examples 3 and 4, but significantly lower than Example 1; the DHA content in the retina is higher than that of Comparative Example 1, and there is no significant difference with Comparative Examples 3 and 4, but significantly lower than Example 1; the BDNF level of brain tissue is significantly higher than that of Comparative Examples 1, 3, and 4, but significantly lower than Example 1; the BDNF level of eye tissue is higher than that of Comparative Example 1, but significantly lower than that of Comparative Example 3 and Example 1; it can be concluded that supplementing with appropriate amounts of linoleic acid and linolenic acid can improve the body's DHA conversion efficiency and brain tissue BDNF level, but it cannot achieve the technical effect of supplementing a specific combination of linoleic acid, linolenic acid, DHA and selenium in Example 1. Although the quality of linoleic acid and linolenic acid supplementation in Example 1 is much lower than that in Comparative Example 2, the synergistic effect of appropriate combinations of linoleic acid, linolenic acid, DHA and selenium in Example 1 achieves unexpected effects in improving the levels of brain tissue DHA and eye and brain tissue BDNF.

[0078] Comparative Example 3 is to supplement DHA under the condition of simulating the daily oil intake of Chinese residents, and the source of DHA is fish oil. By comparison with Comparative Example 1, it can be concluded that DHA alone can promote retinal DHA enrichment and improve the BDNF level of eye tissue, but compared with Comparative Example 2, it can significantly improve the BDNF level of eye tissue, but it cannot be significantly better than the DHA level of eye and brain tissue in Comparative Example 2, proving that DHA supplementation alone cannot exceed the technical effect of sufficient linoleic acid and linolenic acid supplementation in improving the DHA level of eye and brain tissue, and can only significantly improve the BDNF level of eye tissue. The DHA content supplemented in Comparative Example 3 is consistent with that in Example 1. The linoleic acid and linolenic acid content brought in by ordinary milk and native DHA milk are slightly different, resulting in a significant difference in the ratio. There is no significant difference in the ratio and content of linoleic acid and linolenic acid in the overall diet of Comparative Example 3 and Example 1, but the selenium nutrition brought in by native DHA milk in Example 1 is significantly higher than that of ordinary milk, which is one of the reasons why its brain tissue DHA and BDNF level technical effects are significantly better than those of Comparative Example 3.

[0079] Comparative Example 4 is to supplement DHA under the condition of simulating the daily fat intake of Chinese residents. The source of DHA is algae oil, and the amount of DHA fortification fed is about 85% of that of Comparative Example 3 and Example 1. Compared with other comparative examples and examples, only the BDNF level of brain tissue in Comparative Example 4 is significantly higher than that of Comparative Example 1, proving that the decrease in the BDNF level of brain tissue caused by the deficiency of essential fatty acids can be improved under the DHA dose intervened in Comparative Example 4, but its improvement outcome is not as good as the effect of strengthening sufficient linoleic acid and linolenic acid in Comparative Example 2, and the levels of DHA and BDNF in eye and brain tissue are slightly lower than the technical effect of strengthening a higher amount of DHA in Comparative Example 3, and the levels of DHA and BDNF in eye and brain tissue are significantly lower than the synergistic strengthening effect of appropriate linoleic acid and linolenic acid ratio + high amount of DHA + selenium in Example 1.

[0080] Example 1 is to supplement DHA under the condition of simulating the daily fat intake of Chinese residents, and to supplement linolenic acid through cow's milk from feed nutrition regulation. The source of DHA is milk-derived DHA converted by feed nutrition regulation, containing phospholipid DHA; based on the total DHA content of the nutritional composition, the content of the phospholipid DHA is more than 10wt%. By comparing with Comparative Examples 1, 2, 3 and 4, it can be concluded that a specific ratio of linoleic acid, linolenic acid, DHA and selenium can synergistically promote the enrichment of brain tissue and retinal DHA and enhance the level of BDNF in eye and brain tissue.

[0081] Compared with Comparative Example 1, Comparative Example 2 can be concluded that the protection ratio of linoleic acid and linolenic acid can improve the DHA body conversion efficiency; Compared with Comparative Example 1, Comparative Example 3 can be concluded that DHA enhancement helps to improve the DHA richness of eye and brain tissues, but the supplementary effect of this dose of DHA is not better than the effect of optimizing the ratio of linoleic acid and linolenic acid; Compared with Comparative Examples 1-4, Example 1 can be concluded that the combined formula of linoleic acid, linolenic acid, selenium and DHA of the present invention has a synergistic effect, which can achieve the technical effect of improving the DHA body conversion efficiency and significantly improving the DHA richness of eye and brain tissues and the BDNF level of eye and brain tissues.

Claims

1. A nutritional composition capable of increasing the DHA enrichment of eye and brain tissues, wherein: The nutritional composition contains linoleic acid, a-linolenic acid, selenium and DHA; In parts by mass, the linoleic acid is 160-1000 parts, the a-linolenic acid is 18-110 parts, and the DHA is 20-350 parts; The mass ratio of DHA to selenium is (3000-40000):(1-16).

2. The nutritional composition according to claim 1, wherein The mass ratio of linoleic acid to α-linolenic acid is 5:1-11:

1.

3. The nutritional composition according to claim 1, wherein The source of DHA is selected from one or a combination of two or more of milk-derived DHA, algae, tuna oil, fish oil, egg yolk extract, and krill oil through feed nutrition regulation and biotransformation.

4. The nutritional composition according to claim 3, wherein The algae include one or a combination of two or more of Schizochytrium, Oukenhofensis and Crypthecodinium cohnii.

5. The nutritional composition according to claim 3, wherein The milk-derived DHA biotransformed by feed nutrition regulation is native DHA raw milk; Preferably, the native DHA raw milk is prepared according to the feeding and management method of dairy cows in CN 105660520B.

6. The nutritional composition according to claim 1, wherein The source of the linoleic acid includes one or a combination of two or more of soybean oil, walnut oil, corn oil, wheat germ oil, sunflower seed oil, cottonseed oil, sesame oil, peanut oil, rice bran oil, and low-erucic acid rapeseed oil.

7. The nutritional composition according to claim 1, wherein The source of the a-linolenic acid includes one or a combination of two or more of soybean oil, walnut oil, rapeseed oil, linseed oil, perilla oil, peony seed oil, and sacha inchi oil.

8. The nutritional composition according to claim 1, wherein The nutritional composition contains phospholipid DHA; based on the total DHA content of the nutritional composition, the content of the phospholipid DHA is greater than 10 wt%.

9. The nutritional composition according to claim 8, wherein The content of the phospholipid DHA is greater than 15 wt % based on the total DHA content of the nutritional composition.

10. The nutritional composition according to claim 9, wherein Based on the total DHA content of the nutritional composition, the content of the phospholipid DHA is 15wt%-30wt%.

11. The nutritional composition according to claim 1, wherein The source of selenium element includes one or a combination of two or more of sodium selenite, sodium selenate, selenoprotein, selenium-enriched edible fungus powder, L-seleno-methylselenocysteine, selenized carrageenan, and selenium-enriched yeast.

12. Use of the nutritional composition capable of increasing the DHA enrichment in eye and brain tissues according to any one of claims 1 to 11 in the preparation of food capable of increasing the enrichment of DHA in eye and brain tissues; Preferably, increasing the enrichment of DHA in brain tissue refers to increasing the enrichment of DHA in eye and brain tissue in early life.

13. Use of the nutritional composition capable of increasing the DHA enrichment in eye and brain tissues according to any one of claims 1 to 11 in the preparation of food capable of improving the BDNF level in eye and brain tissues.

14. The use according to claim 12 or 13, wherein: The food includes one or a combination of two or more of infant complementary foods, dietary supplements, infant formula powder, infant yogurt, infant cheese, premature infant nutritional enhancers, premature infant formula powder, infant special medical food, health food, dairy products, dairy beverages, snack foods, and pet food.

15. The use according to claim 12 or 13, wherein: In the food, the content of DHA is ≥10 mg / 100 g, and the dosage of selenium is 5-28 μg / 100 g.

Images